Comparison Overview

Mahakam Beta Farma

VS

AbbVie

Mahakam Beta Farma

Jalan Pulo Kambing Raya No 9 Rawa Terate, Jakarta 13920, ID
Last Update: 2025-03-15 (UTC)
Between 750 and 799

We are an innovative, competitive and leading pharmaceutical and healthcare company with strong brands and sustainable double digits growth. We are proud to deliver high quality products and excellent services to our customers so they can have better lives.

NAICS: 325
NAICS Definition:
Employees: 1,001-5,000
Subsidiaries: 0
12-month incidents
0
Known data breaches
0
Attack type number
0

AbbVie

1 Waukegan Road, None, North Chicago, Illinois, US, 60064
Last Update: 2025-09-15 (UTC)
Between 800 and 849

AbbVie is a global biopharmaceutical company focused on creating medicines and solutions that put impact first — for patients, communities, and our world. We aim to address complex health issues and enhance people's lives through our core therapeutic areas: immunology, oncology, neuroscience, eye care, aesthetics and other areas of unmet need. Learn more about us at www.abbvie.com and review our community guidelines at https://www.abbvie.com/social-media-community-guidelines.html.

NAICS: 3254
NAICS Definition: Pharmaceutical and Medicine Manufacturing
Employees: 58,020
Subsidiaries: 15
12-month incidents
0
Known data breaches
1
Attack type number
1

Compliance Badges Comparison

Security & Compliance Standards Overview

https://images.rankiteo.com/companyimages/mahakam-beta-farma.jpeg
Mahakam Beta Farma
ISO 27001
ISO 27001 certification not verified
Not verified
SOC2 Type 1
SOC2 Type 1 certification not verified
Not verified
SOC2 Type 2
SOC2 Type 2 certification not verified
Not verified
GDPR
GDPR certification not verified
Not verified
PCI DSS
PCI DSS certification not verified
Not verified
HIPAA
HIPAA certification not verified
Not verified
https://images.rankiteo.com/companyimages/abbvie.jpeg
AbbVie
ISO 27001
ISO 27001 certification not verified
Not verified
SOC2 Type 1
SOC2 Type 1 certification not verified
Not verified
SOC2 Type 2
SOC2 Type 2 certification not verified
Not verified
GDPR
GDPR certification not verified
Not verified
PCI DSS
PCI DSS certification not verified
Not verified
HIPAA
HIPAA certification not verified
Not verified
Compliance Summary
Mahakam Beta Farma
100%
Compliance Rate
0/4 Standards Verified
AbbVie
0%
Compliance Rate
0/4 Standards Verified

Benchmark & Cyber Underwriting Signals

Incidents vs Pharmaceutical Manufacturing Industry Average (This Year)

No incidents recorded for Mahakam Beta Farma in 2025.

Incidents vs Pharmaceutical Manufacturing Industry Average (This Year)

No incidents recorded for AbbVie in 2025.

Incident History — Mahakam Beta Farma (X = Date, Y = Severity)

Mahakam Beta Farma cyber incidents detection timeline including parent company and subsidiaries

Incident History — AbbVie (X = Date, Y = Severity)

AbbVie cyber incidents detection timeline including parent company and subsidiaries

Notable Incidents

Last 3 Security & Risk Events by Company

https://images.rankiteo.com/companyimages/mahakam-beta-farma.jpeg
Mahakam Beta Farma
Incidents

No Incident

https://images.rankiteo.com/companyimages/abbvie.jpeg
AbbVie
Incidents

Date Detected: 06/2023
Type:Breach
Attack Vector: Exploitation of Vulnerability
Motivation: Financial gain
Blog: Blog

FAQ

AbbVie company demonstrates a stronger AI Cybersecurity Score compared to Mahakam Beta Farma company, reflecting its advanced cybersecurity posture governance and monitoring frameworks.

AbbVie company has historically faced a number of disclosed cyber incidents, whereas Mahakam Beta Farma company has not reported any.

In the current year, AbbVie company and Mahakam Beta Farma company have not reported any cyber incidents.

Neither AbbVie company nor Mahakam Beta Farma company has reported experiencing a ransomware attack publicly.

AbbVie company has disclosed at least one data breach, while Mahakam Beta Farma company has not reported such incidents publicly.

Neither AbbVie company nor Mahakam Beta Farma company has reported experiencing targeted cyberattacks publicly.

Neither Mahakam Beta Farma company nor AbbVie company has reported experiencing or disclosing vulnerabilities publicly.

Neither Mahakam Beta Farma nor AbbVie holds any compliance certifications.

Neither company holds any compliance certifications.

AbbVie company has more subsidiaries worldwide compared to Mahakam Beta Farma company.

AbbVie company employs more people globally than Mahakam Beta Farma company, reflecting its scale as a Pharmaceutical Manufacturing.

Neither Mahakam Beta Farma nor AbbVie holds SOC 2 Type 1 certification.

Neither Mahakam Beta Farma nor AbbVie holds SOC 2 Type 2 certification.

Neither Mahakam Beta Farma nor AbbVie holds ISO 27001 certification.

Neither Mahakam Beta Farma nor AbbVie holds PCI DSS certification.

Neither Mahakam Beta Farma nor AbbVie holds HIPAA certification.

Neither Mahakam Beta Farma nor AbbVie holds GDPR certification.

Latest Global CVEs (Not Company-Specific)

Description

The Bold Page Builder plugin for WordPress is vulnerable to Stored Cross-Site Scripting via the ‘percentage’ parameter in all versions up to, and including, 5.4.5 due to insufficient input sanitization and output escaping. This makes it possible for authenticated attackers, with Contributor-level access and above, to inject arbitrary web scripts in pages that will execute whenever a user accesses an injected page.

Risk Information
cvss3
Base: 6.4
Severity: LOW
CVSS:3.1/AV:N/AC:L/PR:L/UI:N/S:C/C:L/I:L/A:N
Description

The ComboServlet in Liferay Portal 7.4.0 through 7.4.3.111, and older unsupported versions, and Liferay DXP 2023.Q4.0 through 2023.Q4.2, 2023.Q3.1 through 2023.Q3.5, 7.4 GA through update 92, 7.3 GA through update 35, and older unsupported versions does not limit the number or size of the files it will combine, which allows remote attackers to create very large responses that lead to a denial of service attack via the URL query string.

Risk Information
cvss4
Base: 6.9
Severity: LOW
CVSS:4.0/AV:N/AC:L/AT:N/PR:N/UI:N/VC:N/VI:N/VA:L/SC:N/SI:N/SA:N/E:X/CR:X/IR:X/AR:X/MAV:X/MAC:X/MAT:X/MPR:X/MUI:X/MVC:X/MVI:X/MVA:X/MSC:X/MSI:X/MSA:X/S:X/AU:X/R:X/V:X/RE:X/U:X
Description

A relative path traversal vulnerability was discovered in Productivity Suite software version 4.4.1.19. The vulnerability allows an unauthenticated remote attacker to interact with the ProductivityService PLC simulator and delete arbitrary directories on the target machine.

Risk Information
cvss3
Base: 4.0
Severity: HIGH
CVSS:3.1/AV:N/AC:H/PR:N/UI:N/S:C/C:N/I:L/A:N
cvss4
Base: 6.3
Severity: LOW
CVSS:4.0/AV:N/AC:L/AT:P/PR:N/UI:N/VC:N/VI:L/VA:N/SC:N/SI:L/SA:N/E:X/CR:X/IR:X/AR:X/MAV:X/MAC:X/MAT:X/MPR:X/MUI:X/MVC:X/MVI:X/MVA:X/MSC:X/MSI:X/MSA:X/S:X/AU:X/R:X/V:X/RE:X/U:X
Description

A relative path traversal vulnerability was discovered in Productivity Suite software version 4.4.1.19. The vulnerability allows an unauthenticated remote attacker to interact with the ProductivityService PLC simulator and create arbitrary directories on the target machine.

Risk Information
cvss3
Base: 4.0
Severity: HIGH
CVSS:3.1/AV:N/AC:H/PR:N/UI:N/S:C/C:N/I:L/A:N
cvss4
Base: 6.3
Severity: LOW
CVSS:4.0/AV:N/AC:L/AT:P/PR:N/UI:N/VC:N/VI:L/VA:N/SC:N/SI:L/SA:N/E:X/CR:X/IR:X/AR:X/MAV:X/MAC:X/MAT:X/MPR:X/MUI:X/MVC:X/MVI:X/MVA:X/MSC:X/MSI:X/MSA:X/S:X/AU:X/R:X/V:X/RE:X/U:X
Description

A relative path traversal vulnerability was discovered in Productivity Suite software version 4.4.1.19. The vulnerability allows an unauthenticated remote attacker to interact with the ProductivityService PLC simulator and delete arbitrary files on the target machine.

Risk Information
cvss3
Base: 7.5
Severity: HIGH
CVSS:3.1/AV:N/AC:H/PR:N/UI:N/S:C/C:N/I:L/A:H
cvss4
Base: 8.3
Severity: LOW
CVSS:4.0/AV:N/AC:L/AT:P/PR:N/UI:N/VC:N/VI:L/VA:H/SC:N/SI:L/SA:L/E:X/CR:X/IR:X/AR:X/MAV:X/MAC:X/MAT:X/MPR:X/MUI:X/MVC:X/MVI:X/MVA:X/MSC:X/MSI:X/MSA:X/S:X/AU:X/R:X/V:X/RE:X/U:X